| 0.5388 0.044 (8.85%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.72 | 1-year : | 2.46 |
| Resists | First : | 1.47 | Second : | 2.1 |
| Pivot price | 0.54  |
|||
| Supports | First : | 0.44 | Second : | 0.37 |
| MAs | MA(5) : | 0.51 |
MA(20) : | 0.63 |
| MA(100) : | 1.46 |
MA(250) : | 9.7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.8 |
D(3) : | 7.5 |
| RSI | RSI(14): 43.3 |
|||
| 52-week | High : | 37.43 | Low : | 0.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IVF ] has closed above bottom band by 46.5%. Bollinger Bands are 75% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.54 - 0.54 | 0.54 - 0.55 |
| Low: | 0.47 - 0.47 | 0.47 - 0.48 |
| Close: | 0.53 - 0.54 | 0.54 - 0.54 |
INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., is a healthcare services fertility company dedicated to expanding assisted reproductive technology (ART) care. The company focuses on building, acquiring, and operating fertility clinics, including “INVO Centers” offering the intravaginal culture (IVC) procedure enabled by its proprietary INVOcell® medical device. This device allows fertilization and early embryo development to occur in vivo within the woman’s body, providing a more natural, intimate, and affordable alternative to traditional IVF. INVO Fertility operates multiple centers in the U.S. and distributes the INVOcell technology to third-party clinics. The company separated its fertility and oncology businesses in April 2025 to focus exclusively on fertility care.
Wed, 30 Apr 2025
INVO Fertility inks deal, issues new warrants - Investing.com
Fri, 18 Apr 2025
INVO Fertility faces Nasdaq delisting over late 10-K filing - Investing.com
Mon, 14 Apr 2025
NAYA Biosciences Announces Strategic Decision to Separate - GlobeNewswire
Thu, 13 Mar 2025
NAYA Biosciences Announces 1-for-12 Reverse Stock Split Effective March 18, 2025 - Nasdaq
Tue, 19 Nov 2024
NAYA Biosciences, Inc. SEC 10-Q Report - TradingView
Mon, 21 Oct 2024
NAYA - NAYA Biosciences Latest Stock News & Market Updates - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Plans
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 38 (K) |
| Shares Short P.Month | 33 (K) |
| EPS | -92.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -9.06 |
| Profit Margin | 0 % |
| Operating Margin | -85.5 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 1.5 % |
| Gross Profit (p.s.) | 0.58 |
| Sales Per Share | 1.51 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | -0.06 |
| Price to Sales | 0.35 |
| Price to Cash Flow | -0.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|